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OxysterolHepatitis B virus (HBV) entry has been analyzed using infection-susceptible cells, including primary
human hepatocytes, primary tupaia hepatocytes, and HepaRG cells. Recently, the sodium taurocholate
cotransporting polypeptide (NTCP) membrane transporter was reported as an HBV entry receptor. In this
study, we established a strain of HepG2 cells engineered to overexpress the human NTCP gene (HepG2-
hNTCP-C4 cells). HepG2-hNTCP-C4 cells were shown to be susceptible to infection by blood–borne and
cell culture-derived HBV. HBV infection was facilitated by pretreating cells with 3% dimethyl sulfoxide
permitting nearly 50% of the cells to be infected with HBV. Knockdown analysis suggested that HBV infec-
tion of HepG2-hNTCP-C4 cells was mediated by NTCP. HBV infection was blocked by an anti-HBV surface
protein neutralizing antibody, by compounds known to inhibit NTCP transporter activity, and by cyclo-
sporin A and its derivatives. The infection assay suggested that cyclosporin B was a more potent inhibitor
of HBV entry than was cyclosporin A. Further chemical screening identiﬁed oxysterols, oxidized deriva-
tives of cholesterol, as inhibitors of HBV infection. Thus, the HepG2-hNTCP-C4 cell line established in this
study is a useful tool for the identiﬁcation of inhibitors of HBV infection as well as for the analysis of the
molecular mechanisms of HBV infection.
 2013 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Approximately 350 million people are estimated to be infected
with hepatitis B virus (HBV) worldwide [1–4]. Chronically infected
patients are at a greater risk of developing hepatocellular carci-
noma. Currently, clinical treatment for HBV infection includesinterferon (IFN)a and nucleos(t)ide analogs [2,4]. IFNa therapy
yields long-term clinical beneﬁt in less than 40% of the treated
patients and can cause signiﬁcant side effects. Nucleos(t)ide analog
treatment can suppress HBV replication with substantial biochem-
ical and histological improvement; however, such analogs may
select drug-resistant viruses, thereby limiting the efﬁcacy of
long-term treatment. Thus, the development of new anti-HBV
agents targeting a different molecule in the HBV life cycle is
urgently needed.
HBV is a hepatotropic virus that mainly or exclusively infects
human liver [1,5]. HBV infection can be reproduced in cell culture
using primary human hepatocytes (PHH), primary tupaia hepato-
cytes (PTH), and HepaRG cells [6]. Although HBV infection into
these cells is robust, these models have signiﬁcant limitations as
tools for analyzing the mechanisms of HBV infection. Notably,
these models can yield unstable reproducibility among lots and
low tolerability of transfection efﬁciency with plasmid and siRNA:
preparation and culturing of these cells require signiﬁcant
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of the HCV cell culture (HCVcc) system, in which HCV produced
from a JFH-1 strain-based molecular clone can reinfect Huh-7 cells,
greatly contribute to the characterization of the HCV life cycle and
the evaluation of novel anti-HCV drug candidates [7]. However, the
above-noted limitations of HBV-susceptible cells have hampered
analysis of the HBV life cycle and impeded identiﬁcation of new
anti-HBV drug targets. Thus, establishment of a novel cell line
supporting HBV infection is expected to accelerate the molecular
analyses of HBV infection as well as the development of anti-
HBV agents.
Recently, the sodium taurocholate cotransporting polypeptide
(NTCP) membrane transporter was reported as an HBV entry
receptor [8]. NTCP is a sodium-dependent transporter for tauro-
cholic acid, and belongs to a family of solute carrier proteins that
consist of seven members (SLC10A1-A7) [9,10]. NTCP is expressed
at the basolateral membrane of hepatocytes and mediates the
transport of conjugated bile acids and some drugs from portal
blood to the liver [11]. NTCP speciﬁcally interacts with the large
surface protein of HBV, thereby functioning as a viral entry recep-
tor [8].
In this study, we established a strain of HepG2 cells engineered
to overexpress the NTCP-encoding gene. One of these clones, des-
ignated HepG2-hNTCP-C4, was shown to be highly susceptible
for HBV infection, conﬁrming that this infection is mediated by
NTCP and permitting evaluation in these cells of the anti-HBV
activity of various compounds: reduction of HBV infection of
HepG2-hNTCP-C4 cells was observed upon treatment with com-
pounds that blocked HBV entry in other assays and by known
inhibitors of NTCP transporter activity [12]. A small-scale chemical
screen permitted use to identify oxysterols as inhibitors of HBV
infection. Thus, the cell line established in this study is useful for
screening for anti-HBV agents, as well as for analysis of the molec-
ular mechanisms of HBV infection.2. Materials and methods
2.1. Reagents
Dimethyl sulfoxide (DMSO), anti-FLAG antibody (Ab), dextran
sulfate, cholate, progesterone, 22(S)-hydroxycholesterol (OHC),
25-OHC, 20a-OHC, and 7b-OHC were purchased from Sigma.
Ursodeoxycholate was purchased from Tokyo Chemical Industry.
Bromosulfophthalein was from MP biomedicals. Cyclosporin
(Cs)A, CsB, CsC, CsD, and CsH were obtained from Enzo Lifesci-
ences. Anti-HBV surface protein (HBs) Ab was from Abcam. Hepa-
rin was obtained fromMochida Pharmaceuticals. Myrcludex-B was
kindly provided by Dr. Stephan Urban at University Hospital
Heidelberg and was synthesized by CS Bio (Shanghai, China).2.2. Cell culture and plasmid transfection
HepG2 and HepG2-hNTCP-C4 cells were cultured with DMEM/
F-12 + GlutaMax (Invitrogen) supplemented with 10 mM HEPES
(Invitrogen), 200 units/ml penicillin, 200 lg/ml streptomycin, 10%
FBS, 50 lM hydrocortisone and 5 lg/ml insulin in the presence
(HepG2-hNTCP-C4 cells) or absence (HepG2 cells) of 400 lg/ml
G418 (Nacalai). HepAD38 (kindly provided by Dr. Christoph Seeger
at Fox Chase Cancer Center) [13] and HepaRG cells (BIOPREDIC)
were cultured as described previously [14].
An expression plasmid for hNTCP [15] was transfected into
HepG2 cells with TransIT-LT1 (Mirus) according to the manufac-
turer’s instruction to establish HepG2-hNTCP-C4 cells.2.3. HBV preparation and infection
HBV was prepared and infected as described [14]. Except as
noted, the HBV used in this study was genotype D derived from He-
pAD38 cells [13]. HBV was infected into NTCP-expressing HepG2
cells at 6  103 or 1.8  104 genome equivalent (GEq)/cell or into
HepaRG cells at 6  103 GEq/cell. All infections were performed
in the presence of 4% PEG8000 at 37 C for 16 h as previously de-
scribed [14]. Dr. Urban’s group reported that a quantity of more
than 104 GEq/cell (i.e. 1.25  40  104 GEq/cell) of HBV derived
from HepAD38 or HepG2.2.15 cells was required as an inoculum
for efﬁcient infection into HepaRG cells in the presence of 4%
PEG8000 [16]. A limited number of infections were performed with
HBV of genotype C, derived from the serum of an HBV-infected pa-
tient, at 100 GEq/cell.2.4. Real-time PCR and RT-PCR
Real-time PCR for quantiﬁcation of HBV covalently closed circu-
lar (ccc)DNA were performed as described [14]. Isolation of total
RNA from cell lysates and reverse transcription PCR (RT-PCR) using
a One step RNA PCR kit (Takara) were performed as described pre-
viously [17]. Primers used in this study were as follows: 50-AGG-
GAGGAGGTGGCAATCAAGAGTGG-30 and 50-CCGGCTGAAGAACATT
GAGGCACTGG-30 for NTCP, 50-CCATGGAGAAGGCTGGGG-30 and
50-CAAAGTTGTCATGGATGACC-30 for GAPDH, respectively.2.5. Detection of HBs and HBe antigens
HBs antigen was quantiﬁed by ELISA as described previously
[14]. HBe antigen was detected by Chemiluminescent Immuno As-
say (Mitsubishi Chemical Medience).2.6. Southern blot analysis
Isolation of cellular DNA and southern blot analysis to detect
HBV DNAs were performed as described previously [14].2.7. Indirect immunoﬂuorescence analysis
Immunoﬂuorescence was conducted essentially as described
[14] using an anti-HBc Ab (#B0586, DAKO) at a dilution of 1:1000.2.8. Flow cytometry
An aliquot of 1  106 of HepG2 or HepG2-hNTCP-C4 cells was
incubated for 30 min with a 1:50 dilution of anti-NTCP Ab (Ab-
cam), then washed and incubated with a dye-labeled secondary
Ab (Alexa Fluor 488, Invitrogen) at 1:500 dilution in the dark.
Staining and washing were carried out at 4 C in PBS supplemented
with 0.5% bovine serum albumin and 0.1% sodium azide. The sig-
nals were analyzed with Cell Sorter SH8000 (SONY).2.9. siRNA transfection
siRNAs were transfected into the cells at a ﬁnal concentration of
10–30 nM using Lipofectamine RNAiMAX (Invitrogen) according to
the manufacturer’s protocol. siRNAs were purchased from Sigma.2.10. Statistical analyses
Statistical analyses are done with student t-test.
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3.1. Establishment of a cell line susceptible to HBV infection
To establish a cell line permanently expressing NTCP, we trans-
fected an NTCP-encoding plasmid into HepG2 cells and selected
with G418 at 1 mg/ml for 3 weeks. The resultant 9 cell clones were
isolated and NTCP expression was analyzed by RT-PCR. One of
these clones, designated HepG2-hNTCP-C4, was used in the follow-
ing experiments because this speciﬁc clone exhibited high
expression of NTCP and high susceptibility to HBV infection, as
shown below. Speciﬁcally, NTCP mRNA was abundantly expressed
in HepG2-hNTCP-C4 cells, in contrast to little to no expression of
NTCP mRNA in the parental HepG2 cells (Fig. 1A). Consistent with
the mRNA levels, NTCP protein was detected on the cell surface in
HepG2-hNTCP-C4 cells (Fig. 1B). To evaluate HBV infection, these
cells were inoculated with HBV for 16 h and cultured in normal
growth medium for an additional 12 days, and then HBV surface
protein (HBs) and HBe antigens in the culture supernatant as well
as HBV DNAs, covalently closed circular (ccc)DNA, and HBV core
(HBc) in the cells were assessed. The HBV inoculum used in this
experiment was of genotype D, and was derived from the culture
supernatant of HepAD38 cells that produce HBV by depletion of
tetracycline [13]. To conﬁrm that the detected signals were derived
from HBV infection and did not represent non-speciﬁc background,
the cells were incubated with 1 lM Myrcludex-B (or with DMSO
vehicle) for 3 h prior to and for 16 h during HBV infection. Myrclu-
dex-B is a lipopeptide consisting of amino acid residues 2–48 of the
pre-S1 region of HBV, and is known to block HBV entry [18]. RT-PCR
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Fig. 1. Establishment of a cell line susceptible to hepatitis B virus (HBV) infection. (A)
HepG2 and HepG2-hNTCP-C4 cells were detected by RT-PCR. (B) NTCP protein on cell
cytometry. (C-G) HepG2-hNTCP-C4 or the parental HepG2 cells pretreated with or withou
D) for 16 h. After washing out of the free virus and the compounds, the cells were culture
of HBs (C) and HBe antigens (D) secreted in the culture supernatant, and for the presenc
proteins (G) in the cells. rc, dsl, and ss in (F) indicate relaxed circular, double strand linea
protein and nuclear staining, respectively. (H and I) Infection of blood–borne HBV into H
used as an inoculum for the infection assay. Levels for HBs antigen in the culture supernat
means of three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01.Following HBV exposure, little or no HBs and HBe antigens was
detected in the culture supernatant of the parental HepG2 cells,
and little HBc protein was observed in these cells (Fig. 1C, D, and
G). However, these proteins, as well as HBV DNAs and cccDNA,
were detected in HBV-treated HepG2-hNTCP-C4 cells (Fig. 1C–G).
The corresponding signals were signiﬁcantly reduced in the cells
treated with an HBV entry inhibitor, Myrcludex-B, but not in the
cells treated with DMSO (Fig. 1C–G). These data suggested that
HepG2-hNTCP-C4 cells are HBV-susceptible, in contrast to the
parental HepG2 cells. The HepG2-hNTCP-C4 cell line also was sus-
ceptible to infection with HBV genotype C, which was derived from
the serum of an HBV-infected patient (Fig. 1H and I).3.2. HBV susceptibility of HepG2-hNTCP-C4 cells was augmented by
pretreatment with DMSO
It has been reported that a prolonged HBV infection in primary
human hepatocytes can be enhanced by pretreatment with DMSO
[19]. Therefore, we examined whether pretreatment with DMSO
affected HBV infection of HepG2-NTCP-C4 cells. The cells were
pretreated with 3% DMSO for 24 h and then the HBV infectivity
was investigated following the protocol as in Fig. 1. Immunoﬂuo-
rescence analysis revealed that approximately 50% of the DMSO-
pretreated cells were HBc-positive at 12 days post-infection
(Fig. 2A, middle), while only 10–20% of cells were HBc-positive
cells in the absence of pretreatment (Fig. 1G, upper right). The ef-
fect of DMSO pretreatment on HBV susceptibility was both concen-
tration-(Fig. 2B) and time-dependent (Fig. 2C).cccDNAE
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We used knockdown analysis to determine whether HBV
infection of HepG2-hNTCP-C4 cells was mediated by NTCP. Trans-
fection with siRNA against NTCP (si-NTCP) and GAPDH (si-GAP-
DH) speciﬁcally knocked down mRNA for NTCP and GAPDH,
respectively, in HepG2-hNTCP-C4 cells (Fig. 3A). Consistent with
the effect on transcript level, treatment with si-NTCP depleted
NTCP protein on the cell surface (Fig. 3B). The HBV infection
assay, performed as in Fig. 1, indicated that depletion of NTCP
reduced the levels for HBs (Fig. 3C) and HBe antigens (Fig. 3D)
in culture supernatant as well as HBV cccDNA (Fig. 3E) and HBc
protein (Fig. 3F) in the cells at 12 days postinfection with HBV.
These data suggested that HBV infection into HepG2-hNTCP-C4
cells was mediated by NTCP.
3.4. Evaluation of HBV entry inhibitors in HepG2-hNTCP-C4 cells
To determine whether HepG2-hNTCP-C4 cells could be used to
evaluate anti-HBV activity of compounds, we examined the effect
of known entry inhibitors in these cells. The cells were pretreatedRT-PCR
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infection among Cs analogs (Fig. 4E). These data indicate that
HepG2-hNTCP-C4 cells are useful for evaluating the effect of HBV
entry inhibitors.D
si
-G
A
PD
H
si
-N
TC
P
si
R
N
A 
(-)
0
0.2
0.4
0.6
0.8
1
1.2
HBe
H
B
e 
(fo
ld
)
HBs
si
-G
A
PD
H
si
-N
TC
P
si
R
N
A 
(-)
0
0.2
0.4
0.6
0.8
1
1.2
H
B
s 
(fo
ld
)
C
Blue: DAPI
Red: HBc
 HepG2
-NTCP
HepG2-hNTCP-C4)
i-GAPDH
 (HepG2-hNTCP-C4)
si-GAPDHTCP
CP-C4 cells were transfected (for 48 h) with or without [siRNA()] siRNAs against
H were detected by RT-PCR. (B) Parental HepG2 and HepG2-hNTCP-C4 cells were
TCP protein was detected by ﬂow cytometry. The red, blue, and green lines indicate
d with si-GAPDH, and HepG2 cells, respectively. (C–F) The cells prepared as in (A)
s were assayed for levels of secreted HBs (C) and HBe (D) antigens, and cells were
signals in (F) indicate HBc and nuclear staining, respectively.
Fig. 4. Evaluation of HBV entry inhibitors in HepG2-hNTCP-C4 cells. (A) Schematic representation of the experimental procedure for evaluating HBV entry inhibition. HepG2-
hNTCP-C4 cells were pretreated with or without compounds for 3 h and then inoculated with HBV for 16 h. After washing out of free HBV and the compounds, the cells were
cultured with normal culture medium in the absence of compounds for an additional 12 days, and HBs antigen in the culture supernatant and/or HBV cccDNA in the cells
were detected. Black and white bars show period of treatment and without treatment, respectively. (B–G) HepG2-hNTCP-C4 cells were treated with or without 1 lM
Myrcludex-B, 10 lg/ml anti-HBs or anti-FLAG Ab (B); HBV attachment inhibitors including 100 IU/ml heparin and 1 mg/ml dextran sulfate (C); NTCP inhibitors including
100 lM ursodeoxycholate, 100 lM cholate, 40 lM progesterone, and 100 lM bromosulfophthalein (D); cyclosporins (CsA, CsB, CsC, CsD, CsH) at 1, 2, 4, and 8 lM (E); 22(S)-
hydroxycholesterol (OHC) at 11, 33, and 100 lM (F); or oxysterols including 22(S)-OHC, 25-OHC, 20a-OHC, and 7b-OHC at 100 lM (G). For each assay, the cells were infected
with HBV as shown in (A) and the levels of HBs antigen secreted into the culture supernatant and/or cccDNA in the cells were detected. Pretreatment time of compounds in (F)
and (G) was 6 h, instead of 3 h. IC50s of cyclosporin derivatives calculated in this assay are shown below the graph in (E). (H) HepaRG cells were treated with or without
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812 M. Iwamoto et al. / Biochemical and Biophysical Research Communications 443 (2014) 808–813As there are only reverse transcriptase inhibitors currently
available as anti-HBV drugs that inhibit the HBV life cycle, develop-
ment of new anti-HBV agents targeting different steps in the HBV
life cycle are greatly needed [1–4]. We therefore screened for com-
pounds that blocked HBV entry by following the same protocol as
in Fig. 4A. We found that an oxysterol, 22(S)-hydroxycholesterol
(OHC), reduced HBV infection in a dose-dependent manner
(Fig. 4F). Other oxysterols, 25-OHC, 20a-OHC, and 7b-OHC, also
signiﬁcantly decreased HBV infection (Fig. 4G). To validate this
result, we repeated the assay using HepaRG cells, a line that
frequently has been used in HBV entry experiments [14]. We found
that 22(S)-OHC also reduced HBV infection of HepaRG cells in a
dose-dependent manner (Fig. 4H), suggesting that the observed
inhibitory effect of oxysterols reﬂects a genuine inhibition of
HBV infection.
Thus, we have newly established a cell line that is susceptible to
HBV infection. HepG2-hNTCP-C4 cells exhibited approximately
50% of HBV-infection positive cells (Fig. 2A), while maximum
HBV infection of HepaRG cells was reported to be only 7% [16] or
20% [22] of the total population. These cells are expected to be use-
ful for analyzing the molecular mechanisms of HBV infection, given
that HepG2-derived cells show higher efﬁciency of transfection
with expression plasmids and siRNAs than the current availableHBV-susceptible PHH, PTH, and HepaRG cells. HepG2-hNTCP-C4
cells will facilitate knockdown analysis of host factors to deﬁne
their roles in infection and screenings of compounds to identify no-
vel inhibitors of HBV infection. As an example, we demonstrated
here that oxysterols blocked HBV infection. The molecular mecha-
nisms whereby oxysterols inhibit HBV infection are now under
investigation. These analyses will be important for understanding
the mechanisms of HBV infection as well as for developing new
anti-HBV agents.
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